Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: An in vivo bioluminescence imaging study

European Journal of Cancer

Volumn 46, Issue 6, 2010, Pages 1132-1143

  Zeng, Qing ^a   Yang, Zhong ^a   Gao, Yong Jing ^a   Yuan, Huaiping ^a   Cui, Kemi ^b   Shi, Ying ^a   Wang, Hongyun ^c   Huang, Xudong ^a   Wong, Stephen T C ^b   Wang, Yaming ^a   Kesari, Santosh ^d   Ji, Ru Rong ^a   Xu, Xiaoyin ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer metastasis; Cyclophosphamide; HIF 1 ; in vivo bioluminescence imaging; mTOR; Rapamycin; Triple negative breast cancer

Indexed keywords

CD34 ANTIGEN; CELL DNA; CYCLOPHOSPHAMIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; PROTEIN KINASE B; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL FUNCTION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG; LUNG METASTASIS; METASTASIS; MICROENVIRONMENT; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL HYPOXIA; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; FEMALE; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; SIROLIMUS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949659245     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.01.014     Document Type: Article

References (30)

1. Kassam F., Enright K., Dent R., et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 9 1 (2009) 29-33
2. Irvin W.J.J., and Carey L.A. What is triple-negative breast cancer?. Eur J Cancer 44 18 (2008) 2799-2805
3. Stockmans G., Deraedt K., Wildiers H., Moerman P., and Paridaens R. Triple-negative breast cancer. Curr Opin Oncol 20 6 (2008) 614-620
4. Altundag K., Harputluoglu H., Aksoy S., and Gullu I.H. Potential chemotherapy options in the triple negative subtype of breast cancer. J Clin Oncol 25 10 (2007) 1294-1295 [author reply 1295-6]
5. Rakha E.A., El-Sayed M.E., Green A.R., et al. Prognostic markers in triple-negative breast cancer. Cancer 109 1 (2007) 25-32
6. Strimpakos A.S., Karapanagiotou E.M., Saif M.W., and Syrigos K.N. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 35 2 (2009) 148-159
7. Cui X., Zhang P., Deng W., et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17 4 (2003) 575-588
8. Chan S., Scheulen M.E., Johnston S., et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23 23 (2005) 5314-5322
9. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 5 (2004) 909-918
10. Dancey J.E. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 5 9 (2006) 1065-1073
11. Svirshchevskaya E.V., Mariotti J., Wright M.H., et al. Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity. BMC Cancer 8 (2008) 176
12. Noh W.C., Mondesire W.H., Peng J., et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10 3 (2004) 1013-1023
13. Thomas G.V., Tran C., Mellinghoff I.K., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 1 (2006) 122-127
14. Mondesire W.H., Jian W., Zhang H., et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10 20 (2004) 7031-7042
15. Beuvink I., Boulay A., Fumagalli S., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 6 (2005) 747-759
16. Hengstler J.G., Hengst A., Fuchs J., et al. Induction of DNA crosslinks and DNA strand lesions by cyclophosphamide after activation by cytochrome P450 2B1. Mutat Res 373 2 (1997) 215-223
17. Cejka D., Preusser M., Fuereder T., et al. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res 28 6A (2008) 3801-3808
18. Svagzdys S., Lesauskaite V., Pavalkis D., et al. Microvessel density as new prognostic marker after radiotherapy in rectal cancer. BMC Cancer 9 (2009) 95
19. Garber K. Targeting mTOR: something old, something new. J Natl Cancer Inst 101 5 (2009) 288-290
20. Wan X., Harkavy B., Shen N., Grohar P., and Helman L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26 13 (2007) 1932-1940
21. Viola R.J., Provenzale J.M., Li F., et al. In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1alpha, a promoter that protects cells, in response to chemotherapy. AJR Am J Roentgenol 191 6 (2008) 1779-1784
22. Chen Y., Zheng Y., and Foster D.A. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 22 25 (2003) 3937-3942
23. Rankin E.B., and Giaccia A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15 4 (2008) 678-685
24. Toschi A., Lee E., Gadir N., Ohh M., and Foster D.A. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 283 50 (2008) 34495-34499
25. Salceda S., and Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272 36 (1997) 22642-22647
26. Blouw B., Song H., Tihan T., et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4 2 (2003) 133-146
27. Generali D., Fox S.B., Brizzi M.P., et al. Down-regulation of phosphatidylinositol 3′-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 14 9 (2008) 2673-2680
28. Guba M., Koehl G.E., Neppl E., et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 18 1 (2005) 89-94
29. Jenkins D.E., Hornig Y.S., Oei Y., Dusich J., and Purchio T. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 7 4 (2005) R444-R454
30. Cui K., Xu X., Zhao H., and Wong S.T. A quantitative study of factors affecting in vivo bioluminescence imaging. Luminescence 23 5 (2008) 292-295